BlackRock
TPST icon

BlackRock’s Tempest Therapeutics TPST Stock Holding History

BlackRock’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.4K Hold
39,068
– – ﹤0.01% 5221
2026
Q1 		$64.1K Hold
39,068
– – ﹤0.01% 5065
2025
Q4 		$112K Hold
39,068
– – ﹤0.01% 4873
2025
Q3 		$402K Hold
39,068
– – ﹤0.01% 4516
2025
Q2 		$266K Sell
39,068
-4,125
-10% -$29.3K ﹤0.01% 4602
2025
Q1 		$414K Buy
43,193
+742
+2% +$8.42K ﹤0.01% 4446
2024
Q4 		$461K Buy
42,451
+21
+0% +$271 ﹤0.01% 4429
2024
Q3 		$772K Buy
42,430
+104
+0.2% +$2.13K ﹤0.01% 4232
2024
Q2 		$1.21M Buy
42,326
+3,234
+8% +$140K ﹤0.01% 4129
2024
Q1 		$1.99M Sell
39,092
-56
-0.1% -$2.83K ﹤0.01% 4002
2023
Q4 		$2.24M Buy
39,148
+32,758
+513% +$1.55M ﹤0.01% 4003
2023
Q3 		$25.3K Hold
6,390
– – ﹤0.01% 5113
2023
Q2 		$106K Hold
6,390
– – ﹤0.01% 4894
2023
Q1 		$193K Hold
6,390
– – ﹤0.01% 4787
2022
Q4 		$95.5K Hold
6,390
– – ﹤0.01% 5057
2022
Q3 		$144K Hold
6,390
– – ﹤0.01% 5066
2022
Q2 		$178K Hold
6,390
– – ﹤0.01% 5069
2022
Q1 		$280K Hold
6,390
– – ﹤0.01% 5028
2021
Q4 		$438K Buy
6,390
+29
+0.5% +$3.99K ﹤0.01% 4905
2021
Q3 		$1.2M Buy
6,361
+5,983
+1,583% +$1.16M ﹤0.01% 4508
2021
Q2 		$55K Sell
378
-336
-47% -$75.5K ﹤0.01% 5170
2021
Q1 		$167K Buy
714
+63
+10% +$25.5K ﹤0.01% 4771
2020
Q4 		$272K Buy
651
+10
+2% +$3.46K ﹤0.01% 4432
2020
Q3 		$204K Sell
641
-31
-5% -$10.5K ﹤0.01% 4408
2020
Q2 		$231K Sell
672
-2,476
-79% -$988K ﹤0.01% 4345
2020
Q1 		$3.24M Buy
3,148
+541
+21% +$789K ﹤0.01% 3503
2019
Q4 		$3.43M Buy
2,607
+125
+5% +$176K ﹤0.01% 3615
2019
Q3 		$3.44M Buy
2,482
+80
+3% +$129K ﹤0.01% 3592
2019
Q2 		$5.41M Buy
2,402
+2,271
+1,734% +$6.68M ﹤0.01% 3512
2019
Q1 		$382K Hold
131
– – ﹤0.01% 4137
2018
Q4 		$203K Buy
131
+1
+0.8% +$2.06K ﹤0.01% 4230
2018
Q3 		$278K Hold
130
– – ﹤0.01% 4256
2018
Q2 		$345K Sell
130
-26
-17% -$68.5K ﹤0.01% 4191
2018
Q1 		$371K Sell
156
-2
-1% -$6K ﹤0.01% 4091
2017
Q4 		$647K Buy
158
+1
+0.6% +$4.2K ﹤0.01% 4005
2017
Q3 		$650K Sell
157
-3
-2% -$12.8K ﹤0.01% 4011
2017
Q2 		$729K Sell
160
-481
-75% -$2.04M ﹤0.01% 3929
2017
Q1 		$3.51M Buy
641
+639
+31,950% +$2.98M ﹤0.01% 3493
2016
Q4 		$10K Hold
2
– – ﹤0.01% 3396
2016
Q3 		$46K Hold
2
– – ﹤0.01% 2998
2016
Q2 		$30K Buy
2
+1
+100% +$22.8K ﹤0.01% 3137
2016
Q1 		$14K Buy
+1
New +$21.1K ﹤0.01% 3018
2015
Q4 		– Hold
0
– – – 3165
2015
Q3 		– Hold
0
– – – 3081
2015
Q2 		– Hold
0
– – – 2550
2015
Q1 		– Hold
0
– – – 2508
2014
Q4 		– Hold
0
– – – 2400
2014
Q3 		– Hold
0
– – – 2955

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock's TPST Position: Q2 2026 in Review

BlackRock held its Tempest Therapeutics (TPST) position steady in Q2 2026 at 39,068 shares worth $43.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5221.

BlackRock first reported a position in TPST in Q1 2016 and has held it in 42 quarters since. The position peaked at $5.41M in Q2 2019. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • BlackRock held 39,068 shares of Tempest Therapeutics worth $43.4K as of Q2 2026.
  • BlackRock left its Tempest Therapeutics share count unchanged in Q2 2026.
  • Tempest Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5221 holding.
  • BlackRock first reported a position in Tempest Therapeutics in Q1 2016 and has held it in 42 quarters since.
  • BlackRock's Tempest Therapeutics position peaked at $5.41M in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.